[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100500561":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":11,"locations":19,"responsibleParty":39,"collaborators":11,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":11,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":11,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":11,"overallStatus":21,"whyStopped":11,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Brigham and Women's Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention arm","EXPERIMENTAL",null,[13],"Other: Exercise Training",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":11},"Exercise Training","A supervised, personalized exercise training program, which will consist of two 60-minute exercise training sessions per week.",[9],[20],{"facility":5,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"RECRUITING","Boston","Massachusetts","02115","United States","US",{"type":28,"coordinates":29},"Point",[30,31],-71.05977,42.35843,{"lat":31,"lon":30},[34],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"Sarah Cuddy, MD","CONTACT","6177328410","scuddy1@bwh.harvard.edu",{"type":40,"investigatorFullName":35,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Cardiologist","100500561","exercise-training-in-transthyretin-cardiac-amyloidosis-100500561",false,"NCT05797857","Exercise Training in Transthyretin Cardiac Amyloidosis","Personalized Exercise Training to Improve Functional Capacity in Transthyretin Cardiac Amyloidosis","Inclusion Criteria:\n\n* Diagnosis and typing of ATTR-CM by endomyocardial biopsy or by Grade 2 or Grade 3 pyrophosphate (PYP) positivity (exception: nonamyloid control arm in aim 1).\n\n  * Diagnosis of heart failure, with prior or current need of diuretics and increased N-terminal prohormone B-natureitic peptide (BNP) (≥450 pg\u002Fml).\n  * Peak VO2 \\\u003C80% predicted, indicating impaired aerobic capacity (for aim 2 only).\n  * Taking tafamidis (for aim 2 only)\n  * Able to walk 4 meters (with or without the use of an assistive device) and independent with basic activities of daily living at the time of enrolment.\n  * Adequate clinical stability has been achieved in the judgment of the investigator to allow participation in study assessments and the intervention.\n  * Signed informed consent document indicating that the patient understands the purpose of and procedures required for the study and is willing to participate in the study.\n\nExclusion Criteria:\n\n* Acute myocardial infarction (Note: given that cardiac biomarkers such as troponin are frequently elevated in ATTR-CM patients, the diagnosis of acute myocardial infarction should be based on clinical diagnosis, not biomarkers alone)\n\n  * \\>70% obstructive coronary artery disease\n  * Severe aortic valve stenosis\n  * Already actively participating in formal, facility-based cardiac exercise\n  * Already engaging in regular moderate to vigorous exercise conditioning defined as \\> 30 minutes per day, ≥ twice per week consistently during the previous 6 weeks\n  * Ventricular assist device\n  * Light chain amyloidosis or other form of non-ATTR amyloidosis\n  * Advanced chronic kidney disease defined as estimated glomerular filtration rate \\\u003C20 mL\u002Fmin\u002F1.73m2\n  * Any organ transplantation\n  * Terminal illness other than HF with life expectancy \\\u003C 1 year\n  * Pacemaker or implantable cardioverter-defibrillato (ICD) with heart rate limits \\\u003C expected heart rates for exercise and unable to be reprogrammed\n  * Neuropathy due to transthyretin (TTR) mutation\n  * Impairment from stroke, injury or other medical disorder that precludes participation in the intervention\n  * Abnormal cardiopulmonary exercise testing (CPET) finding that requires further investigation and management\n  * Dementia that precludes ability to participate in exercise and follow study protocols\n  * High risk for non-adherence as determined by screening evaluation\n  * Inability or unwillingness to comply with the study requirements","ALL","60 Years","90 Years",{"count":53,"type":54},40,"ESTIMATED","INTERVENTIONAL",[57],"NA","Transthyretin cardiac amyloidosis causes debilitating heart failure in older adults. The proposed research will develop a personalized exercise training program to improve functional capacity in patients on optimal treatment for transthyretin cardiac amyloidosis. This is a vital next step to improve functional capacity and quality of life of people suffering from transthyretin cardiac amyloidosis.",[60,61],"Amyloid Cardiomyopathy","Transthyretin Cardiac Amyloidosis","2025-03-14",{"date":64,"type":65},"2025-03-18","ACTUAL",{"date":67,"type":65},"2024-07-10",{"date":69,"type":54},"2030-06-30",{"name":5,"class":6},1]